Her2 CAR Lentivirus

Our Her2 CAR Lentivirus targets the Her2 protein, offering a strategic approach to treating Her2-positive breast cancer. This vector embodies our dedication to advancing precision medicine and providing targeted therapies for patients with breast cancer.

Check the CAR-T Cell Preparation-Lentivirus Packaging Service

Order information

Description

The creation of GeneMedi’s Her2 CAR Lentivirus is a perfect embodiment of our mission using precision medicine to fight breast cancer. Her2 is encoded by the human epidermal growth factor receptor gene and is overexpressed in 10–20% of breast cancers and is associated with aggressive disease and poor prognosis. Hence our lentivirus targeting Her2 with CAR-T cells is novel therapeutic strategy that have the potential to further advance beyond the current Her2-CAR therapies.

Our designed Her2 CAR Lentivirus is the result of our best efforts and symbolises a targeted approach of targeting Her2 positive cancer cells. The CAR that is introduced by this lentivirus is distinguishable by ability to bind to Her2 with high specificity the process assisting in the differentiation between the actual cancerous cells and the normal ones. This degree of differentiation is of particular relevance to breast cancer since maintaining healthy tissues is almost as important as eradicating malignant ones.

It can not only be used as therapeutic reagent but also plays role as a research reagents to further understand regarding Her2 contribution to the tumor formation and to invent more effective therapeutic strategy. Employing the strictest safety and quality assurance protocols, our Her2 CAR Lentivirus is a vital asset for the development of personalized cancer treatment and has hope for better prognosis in Her2-overexpressed breast cancer patients.